Back to Search
Start Over
CART cell therapy for prostate cancer: status and promise
- Source :
- OncoTargets and Therapy.
- Publication Year :
- 2019
- Publisher :
- Dove Press, 2019.
-
Abstract
- Haiyuan Yu,1,* Jun Pan,1,* Zhicheng Guo,1 Chunhua Yang,1,2 Lijun Mao1,2 1Department of Urinary Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China; 2Jiangsu Key Laboratory of Biological Cancer Therapy, Department of Clinic Institute, Xuzhou Medical University, Xuzhou 221002, China *These authors contributed equally to this work Abstract: In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy. Keywords: prostate cancer, CAR-T cells, adoptive immunotherapy, review
- Subjects :
- OncoTargets and Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 11786930
- Database :
- OpenAIRE
- Journal :
- OncoTargets and Therapy
- Accession number :
- edsair.dovemedicalp..8a8d87a057cdcc283611b11be9c15c05